

1. Record Nr.	UNINA9910960560903321
Titolo	Vaccines for the 21st century : a tool for decisionmaking / / Kathleen R. Stratton, Jane S. Durch, and Robert S. Lawrence, editors ; Committee to Study Priorities for Vaccine Development, Division of Health Promotion and Disease Prevention, Institute of Medicine
Pubbl/distr/stampa	Washington, D.C., : National Academy Press, c2000
ISBN	9786610191840 9780309174985 0309174988 9781280191848 1280191848 9780309564434 0309564433
Edizione	[1st ed.]
Descrizione fisica	1 online resource (472 p.)
Altri autori (Persone)	StrattonKathleen R DurchJane LawrenceRobert S. <1938->
Disciplina	615/.372/072073
Soggetti	Vaccines - Research - United States - Planning Immunization - Research - United States - Planning
Lingua di pubblicazione	Inglese
Formato	Materiale a stampa
Livello bibliografico	Monografia
Note generali	Bibliographic Level Mode of Issuance: Monograph
Nota di bibliografia	Includes bibliographical references and index.
Nota di contenuto	Vaccines for the 21st Century -- Copyright -- Acknowledgments -- Contents -- Executive Summary -- THE ANALYTIC FRAMEWORK -- ETHICAL ISSUES -- RESULTS -- OBSERVATIONS -- 1 Introduction -- CONSIDERATIONS RELATED TO THE MODEL AND THE STUDY -- ORGANIZATION OF THE REPORT -- Charge to the Committee -- Committee Membership and Meetings -- Organization of the Report -- 2 Progress in Vaccine Development -- PRIORITIES OF THE IOM COMMITTEE IN 1985 -- LITIGATION AS A BARRIER TO VACCINE DEVELOPMENT -- Immunization of Pregnant Women -- A CASE STUDY OF SUCCESS -- Disease Burden -- Polio Vaccine Development -- Advantages of Evolving Vaccine Strategies -- ADVANCES IN

BIOTECHNOLOGY AND MOLECULAR IMMUNOLOGY AND NEW OPPORTUNITIES FOR VACCINES -- Fundamental Understanding of Helper T Cells for Antibody Versus CMI Responses, and for Cytotoxicity -- Major Advances in Mucosal Immunity -- Mucosal Immune System Organization -- Molecular Aspects of Virulence and Design of Recombinant Protein Vaccines -- Novel Vaccine Delivery Systems -- Recent Advances in Development of Novel Adjuvants -- Scientific Rationale for Vaccines against Autoimmune Diseases -- Immune Tolerance Induction -- Immune Deviation -- Receptor-Centered Regulation -- Targeting Cytokines or Their Receptors -- Viral Vectors in Autoimmune Therapy -- Preventive Vaccines for Autoimmune Diseases -- 3 Considerations of Candidate Vaccines -- EXCLUSION CRITERIA -- Insufficient Basic Science Information -- Existence of Appropriate Prevention Interventions -- International Burden of Disease -- ADDITIONAL CONSIDERATIONS FOR INCLUSION -- Therapeutic Vaccines -- Programmatic Considerations -- Delivery of Vaccines to Children -- Delivery of Vaccines to Adults -- Delivery of Vaccines to Pregnant Women -- 4 Overview of Analytic Approach and Results -- A COST-EFFECTIVENESS APPROACH. Reasons for Using Cost-Effectiveness Analysis -- Limits of Cost-Effectiveness Analysis -- Ethical Issues -- Analytic Perspectives -- Time Horizon and Discounting -- MODEL OVERVIEW -- Health Benefits: The Denominator -- Quality Adjustments: Weighting -- Morbidity Scenarios -- Quality Adjustments for Average Population Health States -- Disease Incidence and Death Rates -- Time Intervals -- QALYs Gained with Vaccine Use -- Costs: The Numerator -- Cost of Research and Development -- Cost of Vaccine Use -- Health Care Costs -- Vaccine Efficacy and Utilization -- Cost-Effectiveness Ratios -- Exclusions from the Analysis -- EXAMPLES: HYPOTHETICAL VACCINE X -- Target Population -- Program Considerations -- Disease Severity -- Discounting -- An Idealized Scenario -- Summary -- RESULTS -- Challenges -- 5 Review of the Analytic Model -- UNIT OF ANALYSIS -- IMPLEMENTING THE ANALYSIS -- Basic Model -- Performing the Analysis -- CALCULATION OF HEALTH BENEFITS -- Quality-Adjusted Life Years -- Quality-Adjustment Weights Based on the Health Utilities Index -- Steps in the Calculation of Anticipated Health Benefits from Vaccine Use -- Develop Morbidity Scenarios -- Calculate Quality-Adjustment Weights -- Calculate Discounted Quality-Adjusted Life Expectancies -- Establish Age-Specific Incidence and Death Rates -- Calculate Time Intervals for Discounting Future Health Benefits -- Calculate Condition-Related Life Expectancies -- Adjust for the Underlying Health Status of the Population -- Calculate Discounted QALYs for Each Health State -- Calculate Total QALYs Gained with Vaccine Use -- COST FACTORS -- Vaccine Development -- Vaccine Use -- Cost of Care -- VACCINE EFFICACY AND UTILIZATION -- COST-EFFECTIVENESS RATIOS -- 6 Ethical Considerations and Caveats -- ETHICAL AND VALUE JUDGMENTS BUILT INTO THE MODEL -- All QALYs Count Equally. Years of Life at Different Ages Are Weighted by Quality -- The Value of Life Extension with and without Disabilities -- Discount Rates for Costs and Benefits -- Which Benefits and Costs Should Be Counted in the Prioritization Process? -- CONSIDERATIONS OF JUSTICE -- Small Benefits to Many Versus Large Benefits to a Few -- What Priority Should Be Given to the Worst-Off or Sickest? -- Fair Chances Versus Best Outcomes -- CONCLUSION -- 7 Observations -- THE FUNDING OF RESEARCH -- NEGLECTED OPPORTUNITIES FOR VACCINE R&D -- D -- International Considerations -- Small Target Populations -- Liability Concerns -- QUALITATIVE JUDGMENTS -- VACCINE PROGRAM

CONCERNS -- References -- APPENDIX 1 *Borrelia burgdorferi* --
DISEASE BURDEN -- Epidemiology -- Disease Scenarios -- COST
INCURRED BY DISEASE -- VACCINE DEVELOPMENT -- VACCINE
PROGRAM CONSIDERATIONS -- Target Population -- Vaccine Schedule,
Efficacy, and Costs -- RESULTS -- READING LIST -- APPENDIX 2
Chlamydia -- DISEASE BURDEN -- Epidemiology -- Disease Scenarios:
Women -- Disease Scenarios: Men -- Disease Scenarios: Infants --
COSTS INCURRED BY DISEASE -- VACCINE DEVELOPMENT -- VACCINE
PROGRAM CONSIDERATIONS -- Target Population -- Vaccine Schedule,
Efficacy, and Costs -- RESULTS -- READING LIST -- APPENDIX 3
Coccidioides immitis -- DISEASE BURDEN -- Epidemiology -- Disease
Scenarios -- COST INCURRED BY DISEASE -- VACCINE DEVELOPMENT
-- VACCINE PROGRAM CONSIDERATIONS -- Target Population --
Vaccine Schedule, Efficacy, and Costs -- RESULTS -- READING LIST --
APPENDIX 4 Cytomegalovirus -- DISEASE BURDEN -- Epidemiology --
Disease Scenarios -- COST INCURRED BY DISEASE -- VACCINE
DEVELOPMENT -- VACCINE PROGRAM CONSIDERATIONS -- Target
Population -- Vaccine Schedule, Efficacy, and Costs -- RESULTS --
READING LIST -- APPENDIX 5 Enterotoxigenic *E. coli* -- DISEASE
BURDEN -- Epidemiology -- Disease Scenarios.
COST INCURRED BY DISEASE -- VACCINE DEVELOPMENT -- VACCINE
PROGRAM CONSIDERATIONS -- Target Population -- Vaccine Schedule,
Efficacy, and Costs -- RESULTS -- READING LIST -- APPENDIX 6
Epstein-Barr Virus -- DISEASE BURDEN -- Epidemiology -- Disease
Scenarios -- COST INCURRED BY DISEASE -- VACCINE DEVELOPMENT
-- VACCINE PROGRAM CONSIDERATIONS -- Target Population --
Vaccine Schedule, Efficacy, and Costs -- RESULTS -- READING LIST --
APPENDIX 7 *Helicobacter pylori* -- DISEASE BURDEN -- Epidemiology --
Disease Scenarios -- COST INCURRED BY DISEASE -- VACCINE
DEVELOPMENT -- VACCINE PROGRAM CONSIDERATIONS -- Target
Population -- Vaccine Schedule, Efficacy, and Costs -- RESULTS --
READING LIST -- APPENDIX 8 Hepatitis C -- DISEASE BURDEN --
Epidemiology -- Disease Scenarios -- COST INCURRED BY DISEASE --
VACCINE DEVELOPMENT -- VACCINE PROGRAM CONSIDERATIONS --
Target Population -- Vaccine Schedule, Efficacy, and Costs -- RESULTS
-- READING LIST -- APPENDIX 9 Herpes Simplex Virus -- DISEASE
BURDEN -- Epidemiology -- Disease Scenarios -- Oral Infections --
Ocular Infections -- Central Nervous System Infections -- Genital
Infections -- Neonatal Infections -- COST INCURRED BY DISEASE --
Oral and Ocular Infections -- Central Nervous System Infections --
Genital Infections -- Neonatal Infections -- VACCINE DEVELOPMENT --
VACCINE PROGRAM CONSIDERATIONS -- Target Population -- Vaccine
Schedule, Efficacy, and Costs -- RESULTS -- READING LIST -- APPENDIX
10 *Histoplasma capsulatum* -- DISEASE BURDEN -- Epidemiology --
Disease Scenarios -- COST INCURRED BY DISEASE -- VACCINE
DEVELOPMENT -- VACCINE PROGRAM CONSIDERATIONS -- Target
Population -- Vaccine Schedule, Efficacy, and Costs -- RESULTS --
READING LIST -- APPENDIX 11 Human Papillomavirus -- DISEASE
BURDEN -- Epidemiology -- Disease Scenarios -- COST INCURRED BY
DISEASE -- VACCINE DEVELOPMENT.
VACCINE PROGRAM CONSIDERATIONS -- Target Population -- Vaccine
Schedule, Efficacy, and Costs -- RESULTS -- READING LIST -- APPENDIX
12 Influenza A and B -- DISEASE BURDEN -- Epidemiology -- Disease
Scenarios -- COST INCURRED BY DISEASE -- VACCINE DEVELOPMENT
-- VACCINE PROGRAM CONSIDERATIONS -- Target Population --
Vaccine Schedule, Efficacy, and Costs -- RESULTS -- READING LIST --
APPENDIX 13 Insulin-Dependent Diabetes Mellitus -- DISEASE BURDEN
-- Epidemiology -- Disease Scenarios -- COST INCURRED BY DISEASE

-- VACCINE DEVELOPMENT -- VACCINE PROGRAM CONSIDERATIONS --
Target Population -- Vaccine Schedule, Efficacy, and Costs -- RESULTS
-- READING LIST -- APPENDIX 14 Melanoma -- DISEASE BURDEN --
Epidemiology -- Disease Scenarios -- COST INCURRED BY DISEASE --
VACCINE DEVELOPMENT -- VACCINE PROGRAM CONSIDERATIONS --
Target Population -- Vaccine Schedule, Efficacy, and Costs -- RESULTS
-- READING LIST -- APPENDIX 15 Multiple Sclerosis -- DISEASE BURDEN
-- Epidemiology -- Disease Scenarios -- COST INCURRED BY DISEASE
-- VACCINE DEVELOPMENT -- VACCINE PROGRAM CONSIDERATIONS --
Target Population -- Vaccine Schedule, Efficacy, and Costs -- RESULTS
-- READING LIST -- APPENDIX 16 Mycobacterium tuberculosis --
DISEASE BURDEN -- Epidemiology -- Disease Scenarios -- COST
INCURRED BY DISEASE -- VACCINE DEVELOPMENT -- VACCINE
PROGRAM CONSIDERATIONS -- Target Population -- Vaccine Schedule,
Efficacy, and Costs -- RESULTS -- READING LIST -- APPENDIX 17
Neisseria gonorrhea -- DISEASE BURDEN -- Epidemiology -- Disease
Scenarios -- COST INCURRED BY DISEASE -- VACCINE DEVELOPMENT
-- VACCINE PROGRAM CONSIDERATIONS -- Target Population --
Vaccine Schedule, Efficacy, and Costs -- RESULTS -- READING LIST --
APPENDIX 18 Neisseria meningitidis B -- DISEASE BURDEN --
Epidemiology -- Disease Scenarios -- COST INCURRED BY DISEASE --
VACCINE DEVELOPMENT.
VACCINE PROGRAM CONSIDERATIONS.
